A Phase I Study to Determine the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Three Doses of Humanised EGFR Antibody EMD 72000 in Combination With ECX in Patients With Advanced Oesophagogastric Adenocarcinoma.
Phase of Trial: Phase I
Latest Information Update: 07 Dec 2018
At a glance
- Drugs Matuzumab (Primary) ; Capecitabine; Cisplatin; Epirubicin
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Adverse reactions
- Sponsors Merck KGaA
- 01 Feb 2007 Status changed from recruiting to completed
- 18 Aug 2005 New trial record.